The antitumor effect of gefitinib on orthotopic TW2.6/LOXL2 xenograft tumor was fourfold higher than that on controls. Our results indicate that LOXL2 expression is a strong prognostic factor for OSCC and may be used as a marker to identify patients most likely to respond to EGFR-targeted therapy.
6 months ago
Journal
|
IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • LOXL2 (Lysyl Oxidase Like 2)
The cyclicity of circIFITM1 was confirmed by agarose gel electrophoresis and Sanger sequencing, and the stability of circIFITM1 was confirmed by actinomycin D assay...The overexpression of circIFITM1 downregulated miR-802 and upregulated FOXP1. circIFITM1 facilitates the proliferative and invasive abilities via miR-802/FOXP1 in Lovo cells.
In conclusion, a total of 49 DEGs and 11 hub genes in NPC using the integrated bioinformatics analysis. IFIT1 was up-regulated in the NPC cells lines, and IFIT1 may act as an oncogene by promoting NPC cell proliferation, migration, and invasion.
2 years ago
Journal
|
CXCL11 (C-X-C Motif Chemokine Ligand 11) • IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • COL22A1 (Collagen Type XXII Alpha 1 Chain) • COL5A1 (Collagen Type V Alpha 1 Chain)
Notably, siRNA knockdown of p65 reduces IFITM1 expression and a drug-repurposing screen of FDA approved compounds identified parthenolide, an NFκB inhibitor, as a cytotoxic agent for TNBC and an inhibitor of IFITM1 in vitro and in vivo. Overall, our findings suggest that targeting IFITM1 by suppressing interferon-alpha/NFκB signaling represents a novel therapeutic strategy for TNBC treatment.
almost 3 years ago
Journal
|
NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • RELA (RELA Proto-Oncogene)